Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
79.64
+1.16 (1.48%)
At close: Dec 5, 2025, 4:00 PM EST
79.89
+0.25 (0.31%)
After-hours: Dec 5, 2025, 7:54 PM EST
Revolution Medicines Stock Forecast
Stock Price Forecast
The 18 analysts with 12-month price forecasts for Revolution Medicines stock have an average target of 77.11, with a low estimate of 64 and a high estimate of 99. The average target predicts a decrease of -3.18% from the current stock price of 79.64.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Revolution Medicines stock from 18 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 7 | 9 | 10 | 9 | 9 |
| Buy | 5 | 6 | 7 | 6 | 9 | 9 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 13 | 16 | 16 | 18 | 18 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wolfe Research | Wolfe Research | Buy Initiates $75 | Buy | Initiates | $75 | -5.83% | Nov 18, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $71 → $82 | Buy | Maintains | $71 → $82 | +2.96% | Nov 6, 2025 |
| Wedbush | Wedbush | Buy Maintains $77 → $80 | Buy | Maintains | $77 → $80 | +0.45% | Nov 6, 2025 |
| Needham | Needham | Strong Buy Maintains $66 → $72 | Strong Buy | Maintains | $66 → $72 | -9.59% | Nov 6, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $72 → $73 | Strong Buy | Maintains | $72 → $73 | -8.34% | Nov 6, 2025 |
Financial Forecast
Revenue This Year
4.22M
Revenue Next Year
34.37M
from 4.22M
Increased by 714.50%
EPS This Year
-5.71
from -3.58
EPS Next Year
-6.54
from -5.71
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 43.8M | 191.8M | ||||
| Avg | 4.2M | 34.4M | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | 4,446.0% | ||||
| Avg | - | 714.5% | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -5.19 | -4.71 | ||||
| Avg | -5.71 | -6.54 | ||||
| Low | -5.64 | -7.48 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.